Intrexon Corporation (NYSE:XON) had its price objective reduced by Bank of America Corporation from $25.00 to $21.00 in a report issued on Friday. They currently have a neutral rating on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on XON. Zacks Investment Research cut Intrexon Corporation from a hold rating to a sell rating in a report on Thursday, July 13th. Northland Securities set a $30.00 price target on Intrexon Corporation and gave the company a buy rating in a report on Monday, August 7th. BidaskClub cut Intrexon Corporation from a hold rating to a sell rating in a report on Friday, August 4th. Griffin Securities reaffirmed a buy rating and issued a $55.00 price target on shares of Intrexon Corporation in a report on Friday, October 6th. Finally, JMP Securities reaffirmed an outperform rating and issued a $42.00 price target on shares of Intrexon Corporation in a report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Intrexon Corporation has an average rating of Hold and a consensus price target of $38.50.

Intrexon Corporation (NYSE:XON) opened at $12.58 on Friday. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. Intrexon Corporation has a twelve month low of $10.25 and a twelve month high of $32.90.

TRADEMARK VIOLATION WARNING: “Intrexon Corporation (XON) PT Lowered to $21.00” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/14/intrexon-corporation-xon-pt-lowered-to-21-00.html.

In other news, Director Robert B. Shapiro acquired 2,850 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was purchased at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the completion of the transaction, the director now directly owns 43,157 shares in the company, valued at $755,247.50. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 56.30% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Intrexon Corporation by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock worth $106,811,000 after purchasing an additional 147,517 shares during the period. State Street Corp grew its position in shares of Intrexon Corporation by 34.0% during the 1st quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock worth $53,664,000 after buying an additional 687,406 shares during the period. First Trust Advisors LP grew its position in shares of Intrexon Corporation by 3.4% during the 3rd quarter. First Trust Advisors LP now owns 1,588,779 shares of the biotechnology company’s stock worth $30,203,000 after buying an additional 51,691 shares during the period. Peregrine Capital Management LLC grew its position in shares of Intrexon Corporation by 25.3% during the 3rd quarter. Peregrine Capital Management LLC now owns 583,328 shares of the biotechnology company’s stock worth $11,089,000 after buying an additional 117,605 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Intrexon Corporation by 3.5% during the 1st quarter. Geode Capital Management LLC now owns 429,532 shares of the biotechnology company’s stock worth $8,513,000 after buying an additional 14,674 shares during the period. Hedge funds and other institutional investors own 77.28% of the company’s stock.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.